多奈哌齐对脑卒中后失语的治疗效果评价

Therapeutic effect of donepezil on the post-stroke aphasia.

摘要:

目的 探讨多奈哌齐治疗脑卒中后失语的疗效和安全性。方法 脑卒中后失语患者随机分为对照组（38例）及治疗组（38例）。对照组给予常规治疗，治疗组在常规治疗的基础上给予多奈哌齐5 mg，1次/d，共4周。采用西方成套测验（WAB）并计算失语商（AQ）评定患者语言功能。结果 治疗后，两组的WAB、AQ评分均有所提高，但治疗组WAB中的口语表达、听理解、复述等方面评分与对照组相比明显增高，差异有统计学意义（P<0.05）。多奈哌齐对运动性失语、感觉性及传导性失语中的复述言语障碍改善作用明显，但对命名性失语无明显疗效。未见明显药物不良反应。结论 多奈哌齐治疗脑卒中后失语有效且较安全。

Abstract:

Objective To study the efficacy and safety of donepezil in the treatment of post-stroke aphasia.Methods Patients with post-stroke aphasia were randomly divided into twogroups: donepezil treated and control (n=38, each). The control group received a conventional treatment. Beside the conventional treatment, the patients in treated group were given 5 mg donepezil once a day for 4 weeks. The language function of patients was evaluated by western aphasia battery (WAB) and aphasia quotient (AQ).Results The WAB and AQ scores in the two groups increased after treatment. The WAB scores (oral expression, auditory comprehension and retelling) in the donepezil treated group were significantly higher than those in the control group (P<0.05) 4 weeks after treatment. Donepezil had obvious effects on retelling in speech disorders of anandia, sensoryaphasia and conduction aphasia, but anomicaphasia. No significant adverse effects of donepezil were observed.Conclusions Donepezil is effective and safety in the treatment of post-stroke aphasia.